Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

Complicated Intra-abdominal Infection Clinical Trial

Official title:

A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01445678
• Other study ID #: 7625A-004
• Secondary ID: CXA-cIAI-10-09CX
• Status: Completed
• Phase: Phase 3
• Start date: December 23, 2011
• Est. completion date: October 15, 2013

Study information

• Verified date: October 2018
• Source: Cubist Pharmaceuticals LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA-201 Intravenous (IV) infusions (1500mg q8h) and metronidazole (500mg q8h) versus meropenem (1000mg q8h)for the treatment of adults with Complicated Intraabdominal Infections (cIAI).

Description:

Approximately, 500 subjects will be enrolled into this study, randomized 1:1 to receive CXA-201 and metronidazole or comparator (meropenem). Subject participation will require a minimum commitment of 38 days and a maximum of 45 days. An End of Treatment (EOT) visit will occur within 24 hours following the last dose of study drug administration/drug discontinuation. A Test of Cure (TOC)/Safety visit will be conducted 26 to 30 days following the first dose of study drug administration. A Last Follow-up (LFU) visit will be conducted 38 to 45 days after the first dose of study drug.

Other known NCT identifiers

• NCT01445665

Recruitment information / eligibility

• Status: Completed
• Enrollment: 494
• Est. completion date: October 15, 2013
• Est. primary completion date: October 3, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnoses of cIAI.

• Subject requires surgical intervention (e.g., laparotomy, laparoscopic surgery, or percutaneous draining of an abscess) within 24 hours of (before or after) the first dose of study drug.

Exclusion Criteria:

• Simple appendicitis; acute suppurative cholangitis; infected necrotizing pancreatitis; pancreatic abscess; or pelvic infections.

• Complicated intraabdominal infection managed by staged abdominal repair (STAR), open abdomen technique including temporary closure of the abdomen, or any situation where infection source control is not likely to be achieved.

• Use of systemic antibiotic therapy for IAI for more than 24 hours prior to the first dose of study drug, unless there is a documented treatment failure with such therapy.

• Have a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only gram-positive activity [e.g., daptomycin, vancomycin, linezolid] are allowed).

• Severe impairment of renal function (estimated CrCl < 30 mL/min), or requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (< 20 mL/h urine output over 24 hours).

• The presence of hepatic disease at baseline.

• Considered unlikely to survive the 4 to 5 week study period.

• Any rapidly-progressing disease or immediately life-threatening illness (including respiratory failure and septic shock).

• Have a documented history of any moderate or severe hypersensitivity or allergic reaction to any ß-lactam antibacterial (a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment), including cephalosporins, carbapenems, penicillins, or ß-lactamase inhibitors, or metronidazole, or nitroimidazole derivatives.

• Women who are pregnant or nursing.

Related Conditions & MeSH terms

• Communicable Diseases
• Complicated Intra-abdominal Infection
• Infection
• Intraabdominal Infections

Intervention

Drug:
• CXA-201 and metronidazole
CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
• Meropenem
Meropenem IV infusion (1000mg q8h) for 4-14 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cubist Pharmaceuticals LLC

Countries where clinical trial is conducted

United States,  Argentina,  Bulgaria,  Chile,  Croatia,  Estonia,  Germany,  Hungary,  Israel,  Korea, Republic of,  Latvia,  Lithuania,  Moldova, Republic of,  Poland,  Serbia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population	Clinical cure is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.	TOC; 26-30 days after start of study drug administration
Secondary	The Percentage of Subjects With Microbiological Outcome of Success at the TOC Visit in the Microbiologically Evaluable (ME) Population	Success is eradication (absence of the baseline pathogen in a specimen appropriately obtained from the original site of infection) or presumed eradication (absence of material to culture in a subject who was assessed as a clinical cure) for each baseline pathogen	TOC; 26-30 days after start of study drug administration
Secondary	The Percentage of Subjects With Clinical Response at End of Therapy (EOT) Visit in the MITT Population	Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.	EOT; Within 24 hours of last study drug administration
Secondary	The Percentage of Subjects With Clinical Response at End of Therapy in the ME Population	Clinical response is complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antibacterial therapy or surgical or drainage procedure was required for the index infection.	EOT; Within 24 hours of last study drug administration
Secondary	The Percentage of Subjects With Clinical Response at Long Term Follow-Up (LFU) in the MITT Population	Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit.	LFU; 38 to 45 days after first study drug administration
Secondary	The Percentage of Subjects With Clinical Response at LFU Visit in the ME Population	Clinical response is clinical cure at TOC and no signs and symptoms recur or worsen since the TOC visit	LFU; 38 to 45 days after first study drug administration